Promontory Therapeutics to Present Data on PT-112 Mechanism of Action at the Society for Immunotherapy of Cancer's 38th Annual Meeting
26 Oct 2023
Phase 2ImmunotherapyOrphan DrugClinical ResultAACR
Data demonstrate the molecular mechanism underlying PT-112-induced immunogenic cell death in cancer cells
PT-112 is a novel immunogenic small molecule that inhibits ribosomal biogenesis and is currently in Phase 2 clinical development
NEW YORK, Oct. 26, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, will present a poster demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. SITC is taking place November 1-5, 2023 in San Diego.
PT-112 is the subject of ongoing Phase 2 clinical trials for metastatic castrate-resistant prostate cancer and thymic epithelial tumors, and a completed Phase 2a trial in non-small cell lung cancer.
Poster Session Details
Title: Molecular mechanisms of immunogenic cell death driven by PT-112
Abstract Number: 1106
Primary Category: Immune-Stimulants and Immune Modulators
Session Date/Time: Saturday, Nov. 4, 2023, 9:00 am – 8:30 pm PT
Session Location: Exhibit Halls A and B1 – San Diego Convention Center
For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com.
About Promontory Therapeutics
Promontory Therapeutics Inc. is a privately held, clinical stage drug development company focused on small molecule immunotherapy in cancer. The company's lead therapeutic candidate PT-112 has demonstrated single-agent and combination anti-cancer activity and an attractive tolerability profile across three Phase 1 studies. PT-112 is the subject of ongoing Phase 2 clinical trials for metastatic castrate-resistant prostate cancer in the United States and France, thymic epithelial tumors (TETs), and a completed Phase 2a trial in non-small cell lung cancer. The Phase 2 trial for PT-112 in TETs, a rare disease with no FDA approved drug, for which PT-112 has received FDA Orphan Drug designation, is underway with the National Cancer InstituteCancer Institute. As part of its recent research and development expansion into France, Promontory was selected as the first international company member of the Paris-Saclay Cancer Cluster, Europe's emerging biotech hub for oncology.
To learn more about Promontory Therapeutics, visit the company's website here.
CONTACTS:
Brooke Raphael, MS
VP, Strategy & Operations
Tel: +1 (646) 974-6453
Email: [email protected]
Investors:
Stan Musial
Chief Financial Officer
Tel: +1 (646) 222-6932
Email: [email protected]
Media:
Alexis Feinberg
ICR Westwicke
Tel: +1 (203) 939-2225
Email: [email protected]
SOURCE Promontory Therapeutics Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.